期刊文献+

沙格列汀联合胰岛素治疗老年2型糖尿病患者的临床观察 被引量:6

下载PDF
导出
摘要 目的:观察沙格列汀联合胰岛素治疗2型糖尿病的疗效和安全性。方法42例年龄在〉70岁的老年2型糖尿病患者,糖化血红蛋白为7.5%-11%,在胰岛素及阿卡波糖治疗〉1年,血糖仍控制不理想者,在保持原有治疗方案不变的基础上加用沙格列汀5mg,1次/d治疗12周,观察其治疗前后的血糖、糖化血红蛋白、C肽、胰岛素用量、BMI、血肝肾功能,观察低血糖发生率、体重变化情况。结果应用沙格列汀治疗后血糖、糖化血红蛋白、胰岛素用量、BMI均下降,(P〈0.01或P〈0.05),治疗后C肽水平升高(P〈0.05)。结论沙格列汀联合胰岛素治疗老年2型糖尿病患者,降糖效果好,不影响体重及肝肾功能,不增加低血糖发生率,安全性高。
作者 刘颖芳
出处 《浙江临床医学》 2014年第11期1799-1800,共2页 Zhejiang Clinical Medical Journal
  • 相关文献

参考文献7

  • 1张儒雅,陆菊明.DPP-4抑制剂在2型糖尿病治疗中的应用[J].中华内分泌代谢杂志,2011,27(1):101-104. 被引量:75
  • 2陆菊明.2型糖尿病治疗新药沙格列汀的药理及临床评价[J].中国新药杂志,2011,20(21):2039-2043. 被引量:40
  • 3Ali S1, Fonseca V.Saxagliptin overview: special focus on safety and adverse effects.Expert Opin Drug Saf,2013,12(1):103-109. 被引量:1
  • 4Rosenstock J1, Aguilar-Salinas C, Klein E, et aL Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes.Curr Med Res Opin. 2{)09,25(10):2401-11. doi: 10.1185/03007990903178735. 被引量:1
  • 5Wu D1, Li L, Liu C.Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients With type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab,2014,16(l):30-37. 被引量:1
  • 6White WB, Zannad F.Saxagliptin, alogliptin, and cardiovascular outcomes. N EnglJ Med, 2014,370(5):484. 被引量:1
  • 7Barnett AH1, Charbonnel B, Li J, et al.Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and etticacy.Clin Drug lnvestig. 2013,33(10):707-717. 被引量:1

二级参考文献32

  • 1Goke B.Islet cell function:alpha and beta cells-partners towards normoglycaemia.Int J Clin Pract Suppl,2008,(159):2-7. 被引量:1
  • 2Kim MH,Lee MK.The incretins and pancreatic beta-cells:use of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide to cure type 2 diabetes Mellitus.Korean Diabetes J,2010,34:2-9. 被引量:1
  • 3Kim W,Egan JM.The role of incretins in glucose homeostasis and diabetes treatment.Pharmacol Rev,2008,60:470-512. 被引量:1
  • 4Neumiller JJ,Wood L,Campbell RK.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.Pharmacotherapy,2010,30:463-484. 被引量:1
  • 5Deacon CF.Circulation and degradation of GIP and GLP-1.Horm Metab Res,2004,36:761-765. 被引量:1
  • 6Deacon CF,Carr RD,Holst JJ.DPP-4 inhibitor therapy:new directions in the treatment of type 2 diabetes.Front Biosci,2008,13:1780-1794. 被引量:1
  • 7Lankas GR,Leiting B,Roy RS,et al.Dipeptidyl peptidase Ⅳ inhibition for the treatment of type 2 diabetes:potential importance of selectivity over dipeptidyl peptidases 8 and 9.Diabetes,2005,54:2988 -2994. 被引量:1
  • 8Holst JJ,Deacon CF.Inhibition of the activity of dipeptidyl-peptidase Ⅳ as a treatment for type 2 diabetes.Diabetes,1998,47:1663-1670. 被引量:1
  • 9Ahren B,Holst JJ,Martensson H,et al.Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase Ⅳ in mice.Eur J Pharmacol,2000,404:239-245. 被引量:1
  • 10Mari A,Sallas WM,He YL,et al.Vildagliptin,a dipeptidyl peptidase-Ⅳ inhibitor,improves model-assessed beta-cell function in patients with type 2 diabetes.J Clin Endocrinol Metab,2005,90:4888-4894. 被引量:1

共引文献107

同被引文献50

引证文献6

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部